Wu-Yi-Nuo Tang

Wu-Yi-Nuo Tang

Auto-generated profile, based on publicly available information

Wu-Yi-Nuo Tang

Department of Pneumology, Jinhua Hospital of Traditional Chinese Medicine Affiliated to Zhejiang Chinese Medical University, 438 West Shuangxi Road, Jinhua 321017, China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 November 2021 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
WTWu-Yi-Nuo Tang
Wu-Yi-Nuo Tang
JLJingtao Liang
Jingtao Liang
JWJu Wu
Ju Wu
LLLi Liu
Li Liu
MLMing-Zhang Lu
Ming-Zhang Lu
SLShun-Pin Li
Shun-Pin Li
Background. There is no effective therapy for silicosis, and Dahuang Zhechong pill (DHZCP), an ancient Chinese medicine prescription, may have a therapeutic effect on silicosis. This study aims to verify the efficacy and safety of DHZCP in silicosis. Methods. This is a randomized controlled clinical trial done at Panzhihua Second Peoples Hospital (Panzhihua City, Sichuan Province, China). Participants diagnosed with silicosis were recruited and randomized to the conventional treatment group (CG) or DHZCP combined with the conventional treatment group (DG). Forced vital capacity predicted (FVC), diffusing capacity of the lung for carbon monoxide predicted (DLCO), six-minute walk distance (6MWD), peripheral oxygen (SpO2), Kings Brief Interstitial Lung Disease Questionnaire (K-BILD), and safety outcomes were measured at baseline and 9 weeks. Results. Fifty-six participants (28 in each group) completed the study, and 53 of them (26 in DG and 27 in CG) completed pulmonary function. At 9 weeks, compared with no DHZCP, DHZCP treatment was associated with significant improvements in FVC (mean±SD, 95CI) (8.2±3.9, 0.3 to 16.0), DLCO (8.6±3.5, 1.5 to 15.7), SpO2 (3.8±0.7, 2.3 to 5.2), and K-BILD total score (6.0±2.3, 1.4 to 10.7). And, there were no statistical differences of safety outcomes between the two groups. Eight patients accepting DHZCP developed mild diarrhea during the first week, which subsequently resolved on its own. Conclusion. DHZCP could improve the pulmonary function, the quality of life, and the exercise capacity of silicosis patients.

1 January 2025 in Mediators of Inflammation
Verified
Journal Article
Open access
LLLang Li
Lang Li
YZYing Zhu
Ying Zhu
CZChenchong Zhao
Chenchong Zhao
YTYinuo Tangwu
Yinuo Tangwu
LHLvyuan He
Lvyuan He
GLGaochen Lan
Gaochen Lan
Background: Lung cancer oncogenesis involves interactions between immune cells and inflammatory cytokines. However, their causal relationships and mediating mechanism remain unclear. Methods: Using a mediating Mendelian randomization (MR) approach, we analyzed genome‐wide association study (GWAS) data for 731 immune‐cellular phenotypes, 41 cytokines, and eight related lung cancer phenotypes. Results: BAFF-R expression in IgD + CD24 + B cells was positively associated with lung adenocarcinoma (LUAD) risk (odds ratio [OR], 1.0168 [95% confidence interval [CI], 1.0006–1.0332]), mediated by macrophage migration inhibition factor (MIF) with a mediation proportion of 14.2% (95% CI, 0.00007–0.0046). CD39 expression on secreting CD4 Tregs was related to an increased risk of small‐cell lung cancer (SCLC) (OR, 1.0306 [95% CI, 1.0006–1.0616]), mediated by interleukin (IL)‐2 and IL‐6 with mediation proportions of 8.43% (95% CI, 0.00005−0.005) and 5.1% (95% CI, 0.00006–0.003), respectively. CD28 expression on CD39 + CD4 + T cells was positively correlated to lung squamous cell carcinoma (LUSC) risk (OR, 1.0335 [95% CI, 1.009–1.0586]), inversely mediated by IL‐16 (95% CI, −0.01 to −0.0003). Conclusions: These findings reveal the associations between immune cells, inflammatory cytokines, and lung cancer risk, providing insights into cancer diagnosis and treatment.